THE GUT MICROBIOME MATTERS: DEFINING THE ROLE OF GUT MICROBIAL COMPOSITION AND ITS DYNAMICS IN MODULATING THE CAR T-CELL RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMHPHOMA: A PROSPECTIVE, SINGLE-CENTRE STUDY (SIE 2026) - Oct 6, 2026 - Abstract #C001; Pres time: Sep 21, 2026; 11:50 AM - 01:20 PM; Location: HALL 1; "Fecal sam- ples of 59 rrLBCL patients treated with CAR-T (55 axicel, 4 lisocel) were collected at T0, the day before and after lym- phodepletion (LD), the day of infusion, and during fup. Notably, taxa depleted in NR are commonly associated with short-chain fatty acid production and maintenance of gut homeostasis, whereas taxa enriched in NR have been linked to dysbiotic and pro-inflammatory states. Our findings highlight the potential of integrating the microbiome profile into patient assessments not only to predict response to therapy but also to guide personalised treatment strategies."
CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma
|
|
B. Casadei1; A. Bernardi2; G. Conti2; C. Pellegrini1; F. Bonifazi3; S. Turroni4; C. Romano5; S. Blandino1; M. Gentilini5; G. Gabrielli5; A. Farolfi6; M. Roberto5; F. De Felice3; M. Ursi3; A. Desiderio5; G. Rossetti5; E. Maffini3; P. Brigidi2; L. Argnani5; P. L. Zinzani5
|